Fundamental Data for ILMN

ILLUMINA I(NSDQ:ILMN)

Illumina Inc. is a leading developer of next-generation tools for the large-scale analysis of genetic variation and function. The company''s tools will provide information that could be used to improve drugs and therapies, customize diagnoses and treatment, and cure disease. The company is developing a comprehensive line of products that can address the scale of experimentation and the breadth of functional analysis required to achieve the goals of molecular medicine.

# Employees: 1536

Address: 9885 Towne Centre Drive,San Diego,CA,USA

Phone: 858-202-4500

Fax: 858-587-4297

Website: www.illumina.com

Email: pfromen@illumina.com

Sector: Medical

Industry: MED-BIOMED/GENE

Executive Officers

William H. Rastetter (Chmn.; Dir.)

Jay T. Flatley (Presi.; C.E.O.; Dir.)

Christian O. Henry (Sr. V.P.; C.F.O.)

John R. Stuelpnagel DVM (Sr.V.P.; C.O.O.; Dir.; G.M.)

Christian G. Cabou (Sr. V.P.; Gen. Counl.; Sec.,)

Dividend

Ex-Dividend Date: N/A

Annual Dividend: N/A

Current Dividend Yield: N/A

Dividend Paid (3 months): N/A

Indicated Dividend: N/A

Earnings

Last Earnings Date: 9/30/2009

Next Earnings Date(Expected): 2/9/2010

Mean EPS (Next Qtr): $0.18

Mean EPS (Year): $0.77

Mean Estimate(Long Term): $28.32

P/E Ratio(Based on EPS estimate): 37.300

Number of Estimates: 11

Shares Performance

Period	ILMN	Compare to S&P
YTD	9.87 %	-9.08 %
4 Weeks	-10.84 %	-15.36 %
12 Weeks	-20.41 %	-25.89 %

Shares Information

Analyst Coverage: Y

Avg Volume: 3296111

Shares Outstanding: 124M

Market Cap: $3.55B

52 Week High: $43.74

52 Week Low: $19.91

P/E Ratio: 36.690

PEG Ratio: 1.320

Split: On 9/23/2008 ILMN split by factor of 2.000

Earnings Performance

EPS Growth in Last Quarter: -5.56 %

EPS Growth in Last Year: 0.00 %

Sales Growth in Last Quarter: -2.03 %

Sales Growth in Last Quarter: 5.39 %

Financials

Qtr Book Value: $3.55

Cash Flow/Share: $31.19

Change in Payout Ratio: 0.000

Price/Sales: 5.490